Safety and feasibility of targeted agent combinations in solid tumours

[1]  A. Tolcher,et al.  Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma , 2010, Cancer Chemotherapy and Pharmacology.

[2]  C. Swanton.  Intratumor heterogeneity: evolution through space and time. , 2012, Cancer research.

[3]  R. Kurzrock,et al.  BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212). , 2012 .

[4]  K. Flaherty,et al.  Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma. , 2012 .

[5]  P. Philip,et al.  Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer , 2012, Cancer.

[6]  Jeremy S Logue,et al.  Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. , 2012, Genes & development.

[7]  T. Gilmer,et al.  Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations , 2012, Molecular Cancer Therapeutics.

[8]  C. Barrios,et al.  Phase II trial of continuous once‐daily dosing of sunitinib as first‐line treatment in patients with metastatic renal cell carcinoma , 2012, Cancer.

[9]  R. Amato,et al.  Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer. , 2012, Clinical genitourinary cancer.

[10]  P. Casali,et al.  A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  P. Carmeliet,et al.  Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers , 2012, Acta oncologica.

[12]  A. Tolcher,et al.  The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer , 2012, Clinical Cancer Research.

[13]  Sung-Bae Kim,et al.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.

[14]  V. Sondak,et al.  Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438) , 2012, Clinical Cancer Research.

[15]  Michael A. Davies,et al.  Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma , 2012, Clinical Cancer Research.

[16]  J. Stockman,et al.  Everolimus for Advanced Pancreatic Neuroendocrine Tumors , 2012 .

[17]  T. Eberlein.  Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin as First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status , 2012 .

[18]  Giulia Bianchi,et al.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[19]  R. Motzer,et al.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.

[20]  Gaudenz Danuser,et al.  Imaging the coordination of multiple signalling activities in living cells , 2011, Nature Reviews Molecular Cell Biology.

[21]  Gang Han,et al.  Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: Leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma , 2011, International journal of cancer.

[22]  V. Weinberg,et al.  A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma , 2011, Cancer.

[23]  M. Ratain,et al.  Opportunities and challenges in the development of experimental drug combinations for cancer. , 2011, Journal of the National Cancer Institute.

[24]  H. Hurwitz,et al.  A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. , 2011, The oncologist.

[25]  M. Ratain,et al.  A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. , 2011, European journal of cancer.

[26]  A. Chella,et al.  Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  David Pérol,et al.  Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. , 2011, The Lancet. Oncology.

[28]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[29]  J. Hainsworth,et al.  Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Hainsworth,et al.  Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial , 2011, The Lancet.

[31]  J. Bruix,et al.  Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. El-Osta,et al.  Histone deacetylase inhibitors augment doxorubicin-induced DNA damage in cardiomyocytes , 2011, Cellular and Molecular Life Sciences.

[33]  KyungMann Kim,et al.  Phase I Study of Sunitinib and Erlotinib in Advanced Nonsquamous Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[34]  Xavier Paoletti,et al.  Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  K. Pointon,et al.  Sirolimus Therapy for Angiomyolipoma in Tuberous Sclerosis and Sporadic Lymphangioleiomyomatosis: A Phase 2 Trial , 2011, Clinical Cancer Research.

[36]  Lillian L. Siu,et al.  Preclinical development of molecular-targeted agents for cancer , 2011, Nature Reviews Clinical Oncology.

[37]  C. Porta,et al.  Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial , 2011, British Journal of Cancer.

[38]  Michael Thomas,et al.  Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Marcus,et al.  First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[41]  M. Kris,et al.  Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib , 2011, Clinical Cancer Research.

[42]  R. Motzer,et al.  Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma , 2010, American journal of clinical oncology.

[43]  W. T. van der Graaf,et al.  A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer , 2010, British Journal of Cancer.

[44]  James H. Doroshow,et al.  Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements , 2010, Nature Reviews Drug Discovery.

[45]  William Pao,et al.  Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[46]  F. Kim,et al.  Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib , 2010, British Journal of Cancer.

[47]  J. Hainsworth,et al.  Bevacizumab and everolimus in the treatment of patients with metastatic melanoma , 2010, Cancer.

[48]  A. Khorana,et al.  Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  B. Monk,et al.  Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  P. Philip,et al.  Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Helen X. Chen,et al.  Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  G. Giaccone,et al.  Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. , 2010, The Lancet. Oncology.

[53]  J. Soria,et al.  Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC). , 2010 .

[54]  C. Ryan,et al.  A phase II study of sunitinib (S) plus erlotinib (E) in advanced renal carcinoma (RCC). , 2010 .

[55]  A. Scott,et al.  DUX study: A phase II study of evaluating dual targeting of the EGFR using the combination of cetuximab and erlotinib in patients with chemotherapy refractory metastatic colorectal cancer. , 2010 .

[56]  J. Uhm,et al.  NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM. , 2010 .

[57]  J. Kim,et al.  A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC). , 2010 .

[58]  J. Bay,et al.  Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial. , 2010 .

[59]  J. Hainsworth,et al.  Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site , 2010, Cancer.

[60]  J. Hainsworth,et al.  Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  E. Giovannetti,et al.  A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer , 2010, Clinical Cancer Research.

[62]  H. Iwata,et al.  Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer , 2010, Breast Cancer Research and Treatment.

[63]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[64]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[65]  J. Baselga,et al.  Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  K. Gelmon,et al.  Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  T. Mak,et al.  Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic, and Pharmacodynamic Evaluation from an Expansion Cohort , 2010, Molecular Cancer Therapeutics.

[68]  Nicholas Iannotti,et al.  Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  R. Kelley,et al.  A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer , 2010, Cancer Chemotherapy and Pharmacology.

[70]  E. Kohn,et al.  Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity , 2010, British Journal of Cancer.

[71]  M. Prados,et al.  Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  Y. Shyr,et al.  A Phase Ib Trial of Erlotinib, an EGFR Inhibitor, and Everolimus (RAD001), an mTOR Inhibitor, in Patients with Metastatic Breast Cancer. , 2009 .

[73]  Werner Scheuer,et al.  Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. , 2009, Cancer research.

[74]  Linda Mol,et al.  Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. , 2009, The New England journal of medicine.

[75]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[76]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  Helen X. Chen,et al.  A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors , 2009, Clinical Cancer Research.

[78]  Robert Pirker,et al.  Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial , 2009, The Lancet.

[79]  F. Hirsch,et al.  Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  R. Motzer,et al.  Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  J. Dancey,et al.  Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. , 2009, The Lancet. Oncology.

[82]  Jeffrey S. Morris,et al.  Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  J. Baselga,et al.  Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity , 2009, Oncogene.

[84]  C. Bokemeyer,et al.  Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  L. Bosserman,et al.  A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach. , 2009, Clinical breast cancer.

[86]  G. Procopio,et al.  Activity of sunitinib in patients with advanced neuroendocrine tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  J. Thigpen.  Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study , 2009 .

[88]  R. Motzer,et al.  Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. , 2008, Clinical genitourinary cancer.

[89]  R. McLendon,et al.  Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma , 2009, Journal of Neuro-Oncology.

[90]  P. Mischel,et al.  A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM) , 2009, Journal of Neuro-Oncology.

[91]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[92]  Katherine S Panageas,et al.  A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer , 2008, Clinical Cancer Research.

[93]  A. Santoro,et al.  A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[94]  G. Sledge,et al.  A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer , 2008, Clinical Cancer Research.

[95]  F. Cappuzzo,et al.  Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  P. Jänne,et al.  Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma , 2008, Cancer.

[97]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[98]  Lori Minasian,et al.  Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  A. Berkenblit,et al.  Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[100]  Suzanne F. Jones,et al.  Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  Giampietro Gasparini,et al.  Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications , 2008, Nature Clinical Practice Oncology.

[102]  J. Soria,et al.  A phase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): Phase 1 results , 2008 .

[103]  H. Gómez,et al.  Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer , 2008 .

[104]  Mace L. Rothenberg,et al.  Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC) , 2008 .

[105]  W. Scheithauer,et al.  EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  S. Steinberg,et al.  Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer , 2008, Clinical Cancer Research.

[107]  Alan P. Brown,et al.  Cutaneous Lesions in the Rat Following Administration of an Irreversible Inhibitor of erbB Receptors, Including the Epidermal Growth Factor Receptor , 2008, Toxicologic pathology.

[108]  S. Ramalingam,et al.  Dual Inhibition of the Epidermal Growth Factor Receptor with Cetuximab, an IgG1 Monoclonal Antibody, and Gefitinib, A Tyrosine Kinase Inhibitor, in Patients with Refractory Non-small Cell Lung Cancer (NSCLC): A Phase I Study , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[109]  Vincent J Schmithorst,et al.  Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. , 2008, The New England journal of medicine.

[110]  M. Andersson,et al.  Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer , 2008, International Journal of Clinical Oncology.

[111]  Michael W Sill,et al.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  R. Herbst,et al.  Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  R. Figlin,et al.  Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  M. Gonen,et al.  Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  G. Pond,et al.  Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.

[116]  M. Kris,et al.  Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall‐cell lung cancer , 2007, Cancer.

[117]  A. Tee,et al.  Hypoxia-inducible Factor 1α Is Regulated by the Mammalian Target of Rapamycin (mTOR) via an mTOR Signaling Motif* , 2007, Journal of Biological Chemistry.

[118]  John Smeraglia,et al.  Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins , 2007, Journal of Translational Medicine.

[119]  A. Tolcher,et al.  A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies , 2007 .

[120]  Susan M. Chang,et al.  Phase I study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (MG) (NABTC 04–02) , 2007 .

[121]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[122]  Sumithra J. Mandrekar,et al.  Phase I Trial of Sorafenib in Combination with Gefitinib in Patients with Refractory or Recurrent Non–Small Cell Lung Cancer , 2007, Clinical Cancer Research.

[123]  J. Hainsworth,et al.  Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[125]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[126]  Siobhan McCormack,et al.  Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non–small-cell lung, pancreatic, colon, and breast tumors , 2006, Molecular Cancer Therapeutics.

[127]  J. Doroshow,et al.  Drug development in oncology: classical cytotoxics and molecularly targeted agents. , 2006, British journal of clinical pharmacology.

[128]  Daohai Yu,et al.  Preliminary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  J. Verweij,et al.  A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently. , 2006, Journal of Clinical Oncology.

[130]  D. Trisciuoglio,et al.  Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. , 2006, Cancer research.

[131]  R. McLendon,et al.  Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma , 2006, Clinical Cancer Research.

[132]  F. Bruggeman,et al.  Cancer: a Systems Biology disease. , 2006, Bio Systems.

[133]  R. Stahel,et al.  A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma , 2006, Cancer Chemotherapy and Pharmacology.

[134]  B. LaFleur,et al.  Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  J. Hainsworth,et al.  Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[136]  Kevin Carroll,et al.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.

[137]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[138]  Edward S. Kim,et al.  Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[139]  Prakash Chinnaiyan,et al.  Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR) , 2004, Cancer Research.

[140]  H. Sorbye,et al.  Phase II study of short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) in patients with progressive colorectal cancer after irinotecan and 5-fluorouracil (FU) treatment , 2004 .

[141]  Peter Greaves,et al.  First dose of potential new medicines to humans: how animals help , 2004, Nature Reviews Drug Discovery.

[142]  D. Threadgill,et al.  Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies. , 2004, Cancer cell.

[143]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[144]  James K. Ellis,et al.  Induction Paclitaxel, Carboplatin, and Infusional 5‐FU Followed by Concurrent Radiation Therapy and Weekly Paclitaxel/Carboplatin in the Treatment of Locally Advanced Head and Neck Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network , 2002, Cancer journal.

[145]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[146]  M. Campiglio,et al.  Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[147]  P Smith,et al.  Concordance of the toxicity of pharmaceuticals in humans and in animals. , 2000, Regulatory toxicology and pharmacology : RTP.

[148]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[149]  H. Niitani,et al.  [Phase II study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[150]  T. Taguchi,et al.  [Phase I study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.